‘Screen all approach’ for HBV prior to chemotherapy most cost-effective

Screening all patients with solid tumors for hepatitis B before they underwent chemotherapy was the most cost-effective strategy, compared with not screening or only screening high-risk patients, according to a published study.The rates of prior HBV exposure among patients with newly diagnosed cancer ranged from 5.6% to 7.4% and many individuals are unaware of their infection, putting them at a high-risk for HBV reactivation during immunosuppressive therapy or cancer chemotherapy, according to Gauree G. Konijeti, MD, from the Scripps Clinic in California, and colleagues.“DeterminationRead More